Citations

Mayo Clinic

Showing 10 of 108523 citations.

Ketosis Suppression and Ageing (KetoSAge) Part 2: The Effect of Suppressing Ketosis on Biomarkers Associated with Ageing, HOMA-IR, Leptin, Osteocalcin, and GLP-1, in Healthy Females
Cooper, Isabella D. , Kyriakidou, Yvoni , Petagine, Lucy , Edwards, Kurtis , Soto-Mota, Adrián , Brookler, Kenneth H. , Elliott, Bradley , Brookler, Kenneth , Elliott, Bradley T

Biomedicines | July 12, 2024 | Volume: 12 | Issue: 7 | Pages: 1553

10.3390/biomedicines12071553 | PMID 39062126 Get It

Metabolic dysfunctions are among the best documented hallmarks of ageing. Cardiovascular disease, Alzheimer’s disease, cancer, type 2 diabetes mellitus, metabolic-dysfunction-associated steatosis liver disease, and fragility fractures are diseases of hyperinsulinaemia that reduce life and healthspan. We studied the effect of suppressing ketosis in 10 lean (BMI 20.5 kg/m2 ± 1.4), metabolically healthy, pre-menopausal women (age 32.3 ± 8.9 years) maintaining nutritional ketosis (NK) for an average of 3.9 years (± 2.3) who underwent three 21-day phases: nutritional ketosis (NK; P1), suppressed ketosis (SuK; P2), and returned to NK (P3). Ketosis suppression significantly increased insulin, 1.83-fold (p = 0.0006); glucose, 1.17-fold (p = 0.0088); homeostasis model assessment for insulin resistance (HOMA-IR), 2.13-fold (p = 0.0008); leptin, 3.35-fold (p = 0.0010); total osteocalcin, 1.63-fold (p = 0.0138); and uncarboxylated osteocalcin, 1.98-fold (p = 0.0417) and significantly decreased beta-hydroxybutyrate, 13.50-fold (p = 0.0012) and glucagon-like peptide-1 (GLP-1), 2.40-fold (p = 0.0209). Sustained NK showed no adverse health effects and may mitigate hyperinsulinemia. All biomarkers returned to basal P1 levels after removing the intervention for SuK, indicating that metabolic flexibility was maintained with long-term euketonaemia.
Melanoma-Derived Extracellular Vesicles Induce CD36-Mediated Pre-Metastatic Niche
Suman, Shankar , Nevala, Wendy K. , Leontovich, Alexey A. , Ward, Caitlin , Jakub, James W. , Kim, Yohan, Geng, Liyi, Stueven, Noah A. , Atherton, Chathu L., Moore, Raymond M. , Schimke, Jill M. , Lucien, Fabrice , McLaughlin, Sarah A., Lucien, Fabrice , Jakub, James W , Moore, Raymond , Markovic, Svetomir N.

Biomolecules | July 12, 2024 | Volume: 14 | Issue: 7 | Pages: 837

10.3390/biom14070837 | PMID 39062552 Get It

CD36 expression in both immune and non-immune cells is known to be directly involved in cancer metastasis. Extracellular vesicles (EVs) secreted by malignant melanocytes play a vital role in developing tumor-promoting microenvironments, but it is unclear whether this is mediated through CD36. To understand the role of CD36 in melanoma, we first analyzed the SKCM dataset for clinical prognosis, evaluated the percentage of CD36 in lymphatic fluid-derived EVs (LEVs), and tested whether melanoma-derived EVs increase CD36 expression and induce M2-macrophage-like characteristics. Furthermore, we performed a multiplex immunofluorescence (MxIF) imaging analysis to evaluate the CD36 expression and its colocalization with various other cells in the lymph node (LN) of patients and control subjects. Our findings show that cutaneous melanoma patients have a worse clinical prognosis with high CD36 levels, and a higher percentage of CD36 in total LEVs were found at baseline in melanoma patients compared to control. We also found that monocytic and endothelial cells treated with melanoma EVs expressed more CD36 than untreated cells. Furthermore, melanoma-derived EVs can regulate immunosuppressive macrophage-like characteristics by upregulating CD36. The spatial imaging data show that cells in tumor-involved sentinel LNs exhibit a higher probability of CD36 expression than cells from control LNs, but this was not statistically significant. Conclusively, our findings demonstrated that CD36 plays a vital role in controlling the immunosuppressive microenvironment in the LN, which can promote the formation of a protumorigenic niche.
Unmet Need in Early-Onset Parkinson’s Disease: Deep Brain Stimulation and Pregnancy
Mehanna, Raja , Kumar, Kishore R. , Oosterbaan, Annelien M., Post, Bart , Ross, Owen A. , Piemonte, Maria Elisa Pimentel , Fraix, Valérie , Moro, Elena , Tan, Eng‐King , Savica, Rodolfo , Force, on behalf of the EOPD Task, Oosterbaan, Annelien , Ross, Owen A , Kumar, Kishore Raj , Pimentel Piemonte, Maria Elisa , Oosterbaan, Annelien M , Śmiłowska, Katarzyna , Fleisher, Jori , Alcalay, Roy N. , Marras, Connie , Force, on behalf of the EOPD Task

Journal of Parkinson’s Disease | July 12, 2024 | Volume: 14 | Issue: 6 | Pages: 1277-1282

10.3233/jpd-240088 | PMID 38995803 Get It

Pregnancy in women with early-onset Parkinson’s disease (PD) is likely to have a higher frequency given the trend toward increasing maternal age, thus resulting in a greater overlap time between childbearing age and PD risk. Deep brain stimulation (DBS) therapy is nowadays offered to PD patients at earlier stage of the disease, when women can still be pre-menopausal. However, few data are available about DBS safety during pregnancy. From a review of the available literature, only one article was published on this topic so far. Therefore, we have developed a clinical consensus on the safety of DBS during pregnancy in PD patients.
Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review
Schaeffer, Eva , Yılmaz, Rezzak , Louis, Erik K. St. , Noyce, Alastair J. , St Louis, Erik K

Journal of Parkinson’s Disease | July 12, 2024 | Volume: 14 | Issue: s2 | Pages: S307-S319

10.3233/jpd-230428 | PMID 38995800 Get It

The ability to identify individuals in the prodromal phase of Parkinson’s disease has improved in recent years, raising the question of whether and how those affected should be informed about the risk of future disease. Several studies investigated prognostic counselling for individuals with isolated REM sleep behavior disorder and have shown that most patients want to receive information about prognosis, but autonomy and individual preferences must be respected. However, there are still many unanswered questions about risk disclosure or early diagnosis of PD, including the impact on personal circumstances, cultural preferences and specific challenges associated with different profiles of prodromal symptoms, genetic testing or biomarker assessments. This narrative review aims to summarize the current literature on prognostic counselling and risk disclosure in PD, as well as highlight future perspectives that may emerge with the development of new biomarkers and their anticipated impact on the definition of PD.
Association of Anxiety and Unspecified Emotional Distress Obtained from a Medical Records Linkage System with Incident Cognitive Outcomes in a Population-Based Setting
Syrjanen, Jeremy A. , Kremers, Walter K. , Fields, Julie A. , Petersen, Ronald C. , Vassilaki, Maria , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Kremers, Walter K , Krell‐Roesch, Janina , Scharf, Eugene , Knopman, David S.

Journal of Alzheimer’s Disease | July 12, 2024 | Volume: 100 | Issue: 4 | Pages: 1355-1364

10.3233/jad-240213 | PMID 38995789 Get It

Background: Studies that assess cognition prospectively and study in detail anxiety history in the participants’ medical records within the context of brain aging and Alzheimer’s disease are limited. Objective: To examine the associations of anxiety and unspecified emotional distress (UED) acquired throughout a person’s life with prospectively collected cognitive outcomes. Methods: Mayo Clinic Study of Aging participants who were cognitively unimpaired at baseline were included. Anxiety and UED data were abstracted from the medical record using the Rochester Epidemiology Project (REP) resources and were run separately as predictors in our models. The data were analyzed using Cox proportional hazards models for the outcomes of incident mild cognitive impairment (MCI) and dementia and using linear mixed effects models for the outcomes of global and domain specific cognitive z-scores and included key covariates. Results: The study sample ( n = 1,808) had a mean (standard deviation) age of 74.5 (7.3) years and 51.4% were male. Anxiety was associated with increased risk of MCI and dementia and was associated with lower baseline cognitive z-scores and accelerated decline over time in the global, memory, and attention domains. UED was associated with faster decline in all domains except visuospatial but did not show evidence of association with incident cognitive outcomes. These results varied by medication use and timing of anxiety. Conclusions: Anxiety and UED both showed inverse associations with cognition. Utilization of anxiety and UED data from across the life course, as available, from the REP system adds robustness to our results.
Mayo Normative Studies: Amyloid and Neurodegeneration Negative Normative Data for the Auditory Verbal Learning Test and Sex-Specific Sensitivity to Mild Cognitive Impairment/Dementia
Christianson, Teresa J., Pudumjee, Shehroo B. , Polsinelli, Angelina J. , Frank, Ryan D. , Kremers, Walter K. , Fields, Julie A. , Jack, Clifford R. , Knopman, David S. , Graff-Radford, Jonathan, Petersen, Ronald C., Stricker, Nikki H. , Lundt, Emily S. , Jack, Clifford R , Kremers, Walter K , Machulda, Mary M. , Knopman, David S. , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Mielke, Michelle M. , Petersen, Ronald C.

Journal of Alzheimer’s Disease | July 12, 2024 | Volume: 100 | Issue: 3 | Pages: 879-897

10.3233/jad-240081 | PMID 38995784 Get It

Background: Conventional normative samples include individuals with undetected Alzheimer’s disease neuropathology, lowering test sensitivity for cognitive impairment. Objective: We developed Mayo Normative Studies (MNS) norms limited to individuals without elevated amyloid or neurodegeneration (A–N–) for Rey’s Auditory Verbal Learning Test (AVLT). We compared these MNS A–N– norms in female, male, and total samples to conventional MNS norms with varying levels of demographic adjustments. Methods: The A–N– sample included 1,059 Mayo Clinic Study of Aging cognitively unimpaired (CU) participants living in Olmsted County, MN, who are predominantly non-Hispanic White. Using a regression-based approach correcting for age, sex, and education, we derived fully-adjusted T-score formulas for AVLT variables. We validated these A–N– norms in two independent samples of CU ( n = 261) and mild cognitive impairment (MCI)/dementia participants ( n = 392) > 55 years of age. Results: Variability associated with age decreased by almost half in the A–N– norm sample relative to the conventional norm sample. Fully-adjusted MNS A–N– norms showed approximately 7– 9% higher sensitivity to MCI/dementia compared to fully-adjusted MNS conventional norms for trials 1– 5 total and sum of trials. Among women, sensitivity to MCI/dementia increased with each normative data refinement. In contrast, age-adjusted conventional MNS norms showed greatest sensitivity to MCI/dementia in men. Conclusions: A–N– norms show some benefits over conventional normative approaches to MCI/dementia sensitivity, especially for women. We recommend using these MNS A–N– norms alongside MNS conventional norms. Future work is needed to determine if normative samples that are not well characterized clinically show greater benefit from biomarker-refined approaches.
Composite Pulmonary Embolism Shock Score: Another Tool in the Toolbox, but Which Tool Is Best?
Henkin, Stanislav , Krishnathasan, Darsiya , Piazza, Gregory , Henkin, Stanislav

Circulation: Cardiovascular Interventions | July 12, 2024 | Volume: 17 | Issue: 8 | Pages: No page available

10.1161/circinterventions.124.014330 | PMID 38994575 Get It

The Outcomes of Surgical Pulmonary Embolectomy for Pulmonary Embolism: A Meta-Analysis
Rahouma, Mohamed , Al-Thani, Shaikha, Salem, Haitham , Mahmoud, Alzahraa, Khairallah, Sherif , Shenouda, David, Sultan, Batool, Khalil, Leen A. , Alomari, Mohammad , Ali, Mostafa, Makey, Ian A. , Haney, John C. , Mick, Stephanie, Ahmed, Magdy M. El‐Sayed , Khalil, Laila , Haney, John , Rahouma, Mohammed

Journal of Clinical Medicine | July 12, 2024 | Volume: 13 | Issue: 14 | Pages: 4076

10.3390/jcm13144076 | PMID 39064116 Get It

Objectives: The purpose of this study is to assess the efficacy, short- and long-term cardiovascular and non-cardiovascular mortalities and postoperative morbidities of surgical pulmonary embolectomy (SPE) for patients with massive or submassive pulmonary embolism. Methods: A comprehensive literature review was performed to identify articles reporting SPE for pulmonary embolism. The outcomes included in-hospital and long-term mortality in addition to postoperative morbidities. The random effect inverse variance method was used. Cumulative meta-analysis, leave-one-out sensitivity analysis, subgroup analysis and meta-regression were performed. Results: Among the 1949 searched studies in our systematic literature search, 78 studies met our inclusion criteria, including 6859 cases. The mean age ranged from 42 to 65 years. The percentage of males ranged from 25.6% to 86.7%. The median rate of preoperative cardiac arrest was 27.6%. The percentage of contraindications to preoperative systemic thrombolysis was 30.4%. The preoperative systemic thrombolysis use was 11.5%. The in-hospital mortality was estimated to be 21.96% (95% CI: 19.21–24.98); in-hospital mortality from direct cardiovascular causes was estimated to be 16.05% (95% CI: 12.95–19.73). With a weighted median follow-up of 3.05 years, the late cardiovascular and non-cardiovascular mortality incidence rates were 0.39 and 0.90 per person-year, respectively. The incidence of pulmonary bleeding, gastrointestinal bleeding, surgical site bleeding, non-surgical site bleeding and wound complications was 0.62%, 4.70%, 4.84%, 5.80% and 7.2%, respectively. Cumulative meta-analysis showed a decline in hospital mortality for SPE from 42.86% in 1965 to 20.56% in 2024. Meta-regression revealed that the publication year and male sex were associated with lower in-hospital mortality, while preoperative cardiac arrest, the need for inotropes or vasopressors and preoperative mechanical ventilation were associated with higher in-hospital mortality. Conclusions: This study demonstrates acceptable perioperative mortality rates and late cardiovascular and non-cardiovascular mortality in patients who undergo SPE for massive or submassive pulmonary embolism.
An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
Kapoor, Prashant , Pour, Luděk , Lichtman, Eben I. , Mateos, María‐Victoria , Kanagavel, Dheepak , Zhao, Liang , Guillemin‐Paveau, Hélène, Macé, Sandrine , Velde, Helgi van de , Richardson, Paul G. , Dimopoulos, Meletios A , Richardson, Paul Gerard Guy , Nathwani, Nitya , Jelı́nek, Tomáš , Perrot, Aurore , Dimopoulos, Meletios Α. , Huang, Shang‐Yi , Špıčka, Ivan , Chhabra, Saurabh

European Journal of Haematology | July 12, 2024 | Volume: 113 | Issue: 5 | Pages: 593-605

10.1111/ejh.14270 | PMID 38993150 Get It

AbstractObjectivesCluster of differentiation 38 (CD38) is a key target on multiple myeloma (MM) cells. This multi‐centre, Phase 1, single‐agent study (NCT04000282) investigated SAR442085, a novel fragment crystallisable (Fc)‐modified anti‐CD38 monoclonal antibody (mAb), with enhanced affinity towards Fc‐gamma receptor on effector cells in patients with relapsed and/or refractory (RR) MM.MethodsThis study comprised two parts: Part‐A (dose‐escalation involving anti‐CD38 mAb pre‐treated and naïve patients) and Part‐B (dose expansion). Primary endpoints were maximum tolerated dose and recommended Phase 2 dose (RP2D).ResultsThirty‐seven heavily pre‐treated patients were treated in Part A. Part‐B (dose‐expansion) was not studied. Seven dose‐limiting toxicities were reported at DL3, DL5, DL6, and DL7. RP2D was determined to be 5–7·5 mg/kg. Most common treatment‐emergent adverse events were infusion‐related reactions in 70·3% (26/37) patients. Grade ≥3 thrombocytopenia was reported in 48·6% (18/37). Overall response rate was 70% in anti‐CD38 mAb naïve and 4% in anti‐CD38 pre‐treated patients, with a median progression‐free survival of 7·62 (95%CI: 2·858; not calculable) months and 2·79 (95%CI: 1·150; 4·172) months and, respectively.ConclusionsThe efficacy of SAR442085 was promising in anti‐CD38 mAb naïve patients but did not extend to the larger cohort of anti‐CD38 mAb pre‐treated patients. This observation, along with transient high‐grade thrombocytopenia, could potentially limit its clinical use.
Psychiatric Disorders Among 5,800 Patients With Microscopic Colitis: A Nationwide Population-Based Matched Cohort Study
Bergman, David , Roelstraete, Björn , Sun, Jiangwei , Ebrahimi, Fahim , Butwicka, Agnieszka , Pardi, Darrell S. , Ludvigsson, Jonas F.

American Journal of Gastroenterology | July 12, 2024 | Volume: 119 | Issue: 12 | Pages: 2516-2525

10.14309/ajg.0000000000002955 | PMID 38994845 Get It

INTRODUCTION: Microscopic colitis (MC) is an inflammatory condition of the large intestine. Primarily diagnosed in middle-aged and older adults, the incidence of the disease has increased markedly during the past few decades. While MC is associated with a reduced quality of life, large-scale studies on the association with future psychiatric disorders are lacking. METHODS: We conducted a nationwide matched cohort study in Sweden from 2006 to 2021. Through a nationwide histopathology database (the Epidemiology Strengthened by histoPathology Reports in Sweden study), we identified 5,816 patients with a colorectal biopsy consistent with MC. These patients were matched with 21,509 reference individuals from the general population all of whom with no previous record of psychiatric disorders. RESULTS: From 2006 to 2021, 519 patients with MC (median age 64.4 years [interquartile range = 49.5–73.3]) and 1,313 reference individuals were diagnosed with psychiatric disorders (9.9 vs 6.5 events per 1,000 person-years), corresponding to 1 extra case of psychiatric disorder in 29 patients with MC over 10 years. After adjustments, the hazard ratio for psychiatric disorders was 1.57 (95% confidence interval = 1.42–1.74). We found significantly elevated estimates up to 10 years after MC diagnosis and a trend toward higher risk with increasing age. Specifically, we observed increased risks for unipolar depression, anxiety disorders, stress-related disorders, substance abuse, and suicide attempts. In sibling-controlled analysis, the adjusted hazard ratio was 1.76 (95% confidence interval = 1.44–2.15). DISCUSSION: Patients with MC are at increased risk of incident psychiatric disorders compared with the general population.